• Vanda Pharmaceuticals director Charles Cliff Duncan purchased 10,000 shares of common stock across three transactions.
• His direct beneficial ownership rose to 108,701 shares following the purchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-449902), on November 05, 2026, and is solely responsible for the information contained therein.